Business Context and Reporting Period
Company: Medifast, Inc. (NYSE: MED)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: Medifast operates a single reportable segment, recently rebranded from OPTAVIA to Trilivy, focusing on a comprehensive metabolic health system. The company utilizes a direct-to-consumer model supported by a network of independent coaches. As of June 30, 2026, the network consisted of approximately 11,700 active earning coaches.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended June 30, 2026 |
3 Months Ended June 30, 2025 |
6 Months Ended June 30, 2026 |
6 Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenue | $76,384 | $105,555 | $152,428 | $221,283 |
| Gross Profit | $53,396 | $76,644 | $105,152 | $160,888 |
| Gross Margin | 69.9% | 72.6% | 69.0% | 72.7% |
| Operating Loss | $(4,327) | $(1,066) | $(7,622) | $(2,329) |
| Net Income (Loss) | $(3,100) | $2,480 | $(5,222) | $1,708 |
| Diluted EPS | $(0.28) | $0.22 | $(0.47) | $0.15 |
| Cash & Equivalents | $71,910 (as of June 30, 2026) Investment Securities: $97,911 |
|||
| Total Assets | ||||
| Working Capital | $160,470 (Current Assets $202,034 - Current Liab. $41,564) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 27.6% ($29.2M) for the quarter and 31.1% ($68.9M) for the six months compared to the prior year. This was primarily driven by a significant reduction in active earning coaches (11,700 in Q2 2026 vs. 22,800 in Q2 2025) due to competitive pressure from GLP-1 medications and a strategic shift to prioritize productive coaches.
- Profitability: The company reported a net loss of $3.1M for the quarter and $5.2M for the six months, reversing to net income in the prior year periods. Operating losses widened due to lower gross profit and a loss of leverage on fixed costs.
- Other Income: Other income decreased significantly ($2.6M drop in Q2) due to the absence of a $2.6M gain on the sale of LifeMD common stock that occurred in the prior year period. The LifeMD investment was fully sold in Q2 2025.
- Asset Sale: The company recognized a one-time gain of $2.2M from the sale of its Maryland Distribution Center building and land in February 2026.
- Lease Obligations: Total lease liabilities increased substantially due to the commencement of a new headquarters lease in Baltimore and an amendment to the Havre De Grace distribution facility lease, adding approximately $19.4M in right-of-use assets and corresponding liabilities.
Guidance, Outlook, and Risks
- Strategic Transformation: Management is executing a transition from a weight-loss focus to a broader "metabolic health" strategy under the new Trilivy brand. This includes the launch of the "Trilivy Reset Fueling" product line and a new coach compensation plan designed to improve productivity.
- Coach Network Outlook: Management expects the number of active earning coaches to continue declining in 2026 as the company prioritizes network efficiency and productivity over headcount. Average revenue per coach increased 41% year-over-year.
- Competitive Landscape: The filing highlights the rapid adoption of GLP-1 medications as a primary competitive threat, noting that these medications often require lifestyle modifications where Medifast's coaching model can serve as a complementary solution.
- Risks: Key risks include macroeconomic volatility (inflation, tariffs), the continued shift in consumer behavior toward pharmaceutical weight loss solutions, and the success of the Trilivy rebranding initiative.
- Liquidity: The company maintains a strong liquidity position with approximately $169.8M in cash, cash equivalents, and investment securities. No material capital expenditures are expected for current growth initiatives.
Investor Verification Checklist
- Coach Retention Metrics: Verify the trajectory of active earning coaches and the effectiveness of the new compensation plan in stabilizing the network.
- Trilivy Adoption: Monitor early sales data and client acquisition rates for the new Trilivy brand and product lines launched in Q3 2026.
- Fixed Cost Leverage: Assess whether the company can successfully reduce fixed costs to match the lower revenue base and restore operating margins.
- Investment Portfolio: Review the composition and performance of the $97.9M investment portfolio, particularly given the company's reliance on interest income to offset operating losses.
- GLP-1 Market Impact: Evaluate the long-term impact of GLP-1 medication usage on the company's core client base and the viability of the "complementary solution" strategy.